Home Overview Press Room Blog Publications For Students about us
Search

About Medical Gene Transfer


Sometimes called "gene therapy," medical gene transfer involves adding or modifying genes in a person's cells (other than those found in his or her sperm or eggs). The "new" genes are intended to function in ways that would alleviate a medical condition. They would not be passed on to any future generations.


Arguments Pro & Con

Gene transfer may eventually become an effective treatment for some important medical conditions. Clinical trials have been underway since 1990, but so far have been mostly unsuccessful, involved several conflict-of-interest scandals, and produced adverse results including deaths.

Gene transfer has also been proposed for "enhancement" purposes. This application could raise troubling social and ethical questions.



Setting the record straightby Martin H. JohnsonReproductive BioMedicine Online EditorialDecember 1st, 2016A report aiming to set the record straight after some shoddy scientific journalism on mitochondrial transfer.
“3-Parent Baby” Procedure Faces New Hurdleby Karen WeintraubScientific AmericanNovember 30th, 2016Mitochondrial disease can somehow creep back in, even if a mother’s mitochondria are virtually eliminated in an attempt to block inherited illnesses.
Review of Blame: A Novelby Abby Lippman, Biopolitical Times guest contributorNovember 28th, 2016Blame is especially important for those unfamiliar with the range of ethical, social, legal, and political issues raised by applications of what is learned in a lab. While a work of fiction, it is definitely not science-fiction
DNA-editing breakthrough could fix 'broken genes' in the brain, delay ageing and cure incurable diseasesby Ian JohnstonThe Independent [UK]November 16th, 2016The technique allows DNA changes that have not previously been possible, modifying the genes of non-dividing cells in a living animal.
CRISPR gene-editing tested in a person for the first timeby David CyranoskiNature NewsNovember 15th, 2016A clinical trial in China used cells edited with CRISPR-Cas9 to treat a patient with lung cancer. Spectators anticipate a biomedical duel with US.
Stem Cell Clinics Promise Miracle Cures, but at What Cost to Patients?by Philip PerryBig ThinkNovember 13th, 2016Taking advantage of a regulatory loophole, hundreds of clinics with virtually no oversight are offering stem cell therapies which are virtually untested, and make unsubstantiated claims about helping patients overcome disease.
San Diego Scientists Help Develop New Twist On In Vitro Fertilizationby David WagnerKPBSNovember 10th, 2016The patent holder for a related "3-person IVF" technique reports new work with "polar body genome transfer." Some experts say none of these approaches have been proven safe.
Dangers of an Unscientific Policy Process:
Why the UK’s legalization of “three-person babies” should not be the model for CRISPR
by Jessica Cussins, Biopolitical Times guest contributorOctober 25th, 2016The UK’s consideration of the science and public support for “mitochondrial replacement” may seem robust on its surface, but when it comes to CRISPR germline genome editing policy, we can and must do better.
First Spindle Nuclear Transfer Baby Has Low Mutant DNA Loadby Kate JohnsonMedscapeOctober 20th, 2016At the ASRM Scientific Congress, fertility doctors said they would continue using the mitochondrial manipulation procedure.
Crispr’s IPO doesn’t hit its targetby Robert WeismanThe Boston GlobeOctober 19th, 2016CRISPR Therapeutics' public offering raises half that of its rivals Editas & Intellia -- a sign that the market may be pulling back on genome editing stocks.
Displaying 1-10 of 348  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760